Antibiotics in Parkinson’s Disease
Parkinson’s Foundation hospital safety guidance identifies specific non-antibiotic drug classes to avoid in Parkinson disease and states metoclopramide, prochlorperazine, promethazine, and droperidol are contraindicated. [1] The same Parkinson’s Foundation guidance does not list any antibiotics as contraindicated for Parkinson disease. [1]
Contraindicated Medication Concepts in Parkinson Disease
Parkinson disease drug contraindications in hospital guidance are driven primarily by medications with dopamine-blocking or strong neuroleptic effects, which can worsen parkinsonism. [1]
- Prochlorperazine (Compazine) is listed as contraindicated. [1]
- Metoclopramide (Reglan) is listed as contraindicated. [1]
- Promethazine (Phenergan) is listed as contraindicated. [1]
- Droperidol (Inapsine) is listed as contraindicated. [1]
Antibiotics With Parkinson-Related Caution: Fluoroquinolones
Fluoroquinolones have safety communications describing risk of serious, disabling, and potentially irreversible adverse effects and emphasize restricting use to situations where benefits outweigh risks. [2] Fluoroquinolones therefore are not listed as Parkinson disease contraindications in the Parkinson’s Foundation guidance, but they require extra vigilance for adverse neuropsychiatric effects in older adults and higher-risk patients. [2][1]
Antibiotics With Parkinson-Related Caution: Macrolides
A pharmacokinetic study in healthy volunteers demonstrated that the macrolide spiramycin alters the pharmacokinetics of L-dopa and carbidopa. [3] This interaction supports medication review for potential effects on Parkinson symptom control when co-administered with levodopa-containing regimens. [3]
Practical Medication-Selection Approach
Antibiotic selection should follow standard infection-specific indications rather than Parkinson disease contraindication lists, because Parkinson disease guidance identifies contraindications for dopamine-blocking antiemetics/neuroleptics rather than antibiotics. [1]
- Medication review should target drugs with known central dopaminergic blockade risk. [1]
- For antibiotics with known CNS or Parkinson-relevant pharmacokinetic effects (including fluoroquinolones and spiramycin), increased monitoring for neuropsychiatric adverse effects or changes in levodopa effect is appropriate. [2][3]
Common Pitfalls to Avoid
Avoidance errors typically involve confusion between Parkinson disease contraindications and antibiotic choice. [1] The Parkinson’s Foundation hospital safety guide explicitly lists contraindicated antiemetics/neuroleptics and does not identify antibiotics as contraindicated in Parkinson disease. [1]